1,3-bis(2-(thiophen-2-yl)ethyl)urea | 68327-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 1,3-bis(2-(thiophen-2-yl)ethyl)urea
• 英文别名: Urea, N,N'-bis[2-(2-thienyl)ethyl]-；1,3-bis(2-thiophen-2-ylethyl)urea
• CAS: 68327-67-3
• 化学式: C₁₃H₁₆N₂OS₂
• 分子量: 280.415
• InChiKey: DCSWIZIJVTYMHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  97.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  丙二酸 、 1,3-bis(2-(thiophen-2-yl)ethyl)urea 在 乙酸酐 、 溶剂黄146 作用下， 反应 4.5h， 生成 1,3-bis(2-(thiophen-2-yl)ethyl)pyrimidine-2,4,6(1H,3H,5H)-trione
  参考文献：
  名称：

  Pyrimidine-2,4,6-trione Derivatives and Their Inhibition of Mutant SOD1-Dependent Protein Aggregation. Toward a Treatment for Amyotrophic Lateral Sclerosis

  摘要：

  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons, leading to muscle weakness, paralysis, and death, most often from respiratory failure. The only FDA-approved drug for the treatment of ALS, riluzole, only extends the median survival in patients by 2-3 months. There is an urgent need for novel therapeutic strategies for this devastating disease. Using a high-throughput screening assay targeting an ALS cultured cell model (PC12-G93A-YFP cell line), we previously identified three chemotypes that were neuroprotective. We present a further detailed analysis of one promising scaffold from that group, pyrimidine-2,4,6-triones (PYTs), characterizing a number of PYT analogues using SAR and ADME. The PYT compounds show good potency, superior ADME data, low toxicity, brain penetration, and excellent oral bioavailability. Compounds from this series show 100% efficacy in the protection assay with a good correlation in activity between the protection and protein aggregation assays. The modifications of the PYT scaffold presented here suggest that this chemical structure may be a novel drug candidate scaffold for use in clinical trials in ALS.

  DOI：

  10.1021/jm101549k
• 作为产物：
  描述：

  噻吩乙胺 以40%的产率得到
  参考文献：
  名称：

  BURAKOWSKI T. J.; MUSZYNSKI E.; PETRUCZENKO A., ACTA POL. PHARM., 1978, 35, NO 2, 175-179

  摘要：

  DOI：

文献信息

• Concise and Additive‐Free Click Reactions between Amines and CF₃SO₃CF₃
  作者：Hai‐Xia Song、Zhou‐Zhou Han、Cheng‐Pan Zhang

  DOI：10.1002/chem.201901865

  日期：2019.8.14

  The reactions are rapid, efficient, selective, and versatile, and can be performed in benign solvents, giving products in excellent yields with minimal efforts for purification. The characteristics of the reactions meet the requirements of a click reaction. The use of trifluoromethyl trifluoromethanesulfonate as a click reagent is advantageous over other "CO" sources (e.g., TsOCF3 , PhCO2 CF3 , CsOCF3

  已证明三氟甲基三氟甲磺酸盐是二氟光气的极佳储存库，并且在无金属和无添加剂条件下制备尿素衍生物，杂环和氨基甲酰氟时，很有希望实现胺的点击连接。该反应快速，高效，选择性和通用，并且可以在良性溶剂中进行，从而以极少的纯化工作即可获得高收率的产物。反应的特征满足点击反应的要求。与其他“ CO”源（例如TsOCF3，PhCO2 CF3，CsOCF3，AgOCF3和三光气）相比，使用三氟甲基三氟甲磺酸盐作为点击试剂是有利的。易于扩展；甚至在无金属和无添加剂的条件下也具有高反应活性。
• Pyrimidine-2,4,6-trione Derivatives and Their Inhibition of Mutant SOD1-Dependent Protein Aggregation. Toward a Treatment for Amyotrophic Lateral Sclerosis
  作者：Guoyao Xia、Radhia Benmohamed、Jinho Kim、Anthony C. Arvanites、Richard I. Morimoto、Robert J. Ferrante、Donald R. Kirsch、Richard B. Silverman

  DOI：10.1021/jm101549k

  日期：2011.4.14

  Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons, leading to muscle weakness, paralysis, and death, most often from respiratory failure. The only FDA-approved drug for the treatment of ALS, riluzole, only extends the median survival in patients by 2-3 months. There is an urgent need for novel therapeutic strategies for this devastating disease. Using a high-throughput screening assay targeting an ALS cultured cell model (PC12-G93A-YFP cell line), we previously identified three chemotypes that were neuroprotective. We present a further detailed analysis of one promising scaffold from that group, pyrimidine-2,4,6-triones (PYTs), characterizing a number of PYT analogues using SAR and ADME. The PYT compounds show good potency, superior ADME data, low toxicity, brain penetration, and excellent oral bioavailability. Compounds from this series show 100% efficacy in the protection assay with a good correlation in activity between the protection and protein aggregation assays. The modifications of the PYT scaffold presented here suggest that this chemical structure may be a novel drug candidate scaffold for use in clinical trials in ALS.
• BURAKOWSKI T. J.; MUSZYNSKI E.; PETRUCZENKO A., ACTA POL. PHARM., 1978, 35, NO 2, 175-179
  作者：BURAKOWSKI T. J.、 MUSZYNSKI E.、 PETRUCZENKO A.

  DOI：——

  日期：——